Abstract
Hospitalization for heart failure (HHF) is commonly associated with symptomatic improvement in response to standard medical therapy, yet there remains a substantial risk of rehospitalization and death. Clinically stable outpatients and decompensated inpatients represent two types of patients with chronic heart failure. In the former, treatment of common heart rhythm disorders with nonpharmacologic electrophysiology-based interventions is of substantial benefit in select patients. The potential benefits of these interventions in the hospitalized setting are not well studied. In this review, current knowledge is discussed and future research directions are suggested with nonpharmacologic electrophysiology-based interventions to reduce the morbidity and mortality associated with patients with HHF.
Original language | English (US) |
---|---|
Pages (from-to) | 331-343 |
Number of pages | 13 |
Journal | Heart Failure Clinics |
Volume | 9 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2013 |
Funding
Dr Piccini has received grants for clinical research from Boston Scientific and Johnson & Johnson; is a consultant for Forest Laboratories, Johnson&Johnson, Medtronic, and Sanofi-Aventis. Dr Fonarowis a consultant for Novartis, Medtronic, and Gambro. Dr Knight receives fellowship support from Bard, Biosense Webster, Biotronik, Medtronic, and St Jude Medical; is a speaker for Biosense Webster, Biotronik, Boston Scientific, Medtronic, and St Jude Medical; is a consultant for Biosense Webster, Boston Scientific, and Cameron Health; and is an investigator for Biotronik, Cameron Health, Medtronic, and St Jude Medical. Dr Butler is an investigator for Medtronic, Boston Scientific, and GE Healthcare. Dr Gheorghiade is a consultant for Abbott Laboratories, Astellas, AstraZeneca, Bayer Schering Pharma, CorThera, Cytokinetics Inc, DebioPharm, Errekappa Therapeuitici, GlaxoSmithKline, Johnson & Johnson, Medtronic, Merck, Novartis Pharma, Otsuka Pharmaceuticals, Pericor Therapeutics, Protein Design Laboratories, Sanofi-Aventis, Sigma Tau, and Solvay Pharmaceuticals. All other authors have reported that they have no relationships to disclose relevant to the contents of this article.
Keywords
- Electrophysiology
- Heart failure
- Hospitalization
- Outcomes
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine